{"id":6803,"date":"2011-03-09T17:05:04","date_gmt":"2011-03-09T22:05:04","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=6803"},"modified":"2011-07-19T17:44:31","modified_gmt":"2011-07-19T21:44:31","slug":"active-i-examines-role-for-irbesartan-in-af-patients","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/03\/09\/active-i-examines-role-for-irbesartan-in-af-patients\/","title":{"rendered":"ACTIVE I Examines Role for Irbesartan in AF Patients"},"content":{"rendered":"<p>The angiotensin-receptor blocker irbesartan does not significantly reduce cardiovascular events in patients with atrial fibrillation, according to\u00a0<a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1008816\">the results of the\u00a0Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE I), published in the<em> New England Journal of Medicine<\/em><\/a>. Participants had been previously randomized in the\u00a0<a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0901301\">ACTIVE A trial<\/a> or the\u00a0<a href=\"http:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(06)68845-4\/abstract\">ACTIVE W trial<\/a>.<\/p>\n<p>More than 9,000 patients were randomized to irbesartan or placebo and followed for 4.1 years. Although patients treated with irbesartan had a significantly greater drop in blood pressure, there were no significant differences in either the first coprimary endpoint\u00a0\u2014 the composite outcome of\u00a0stroke, myocardial infarction, or death from vascular causes\u00a0\u2014 or the second coprimary outcome, which consisted of the first composite outcome plus heart failure hospitalization. However, even though most patients were already taking an ACE inhibitor,\u00a0there were significantly fewer hospitalizations for heart failure in the irbesartan group, a prespecified secondary outcome.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The angiotensin-receptor blocker irbesartan does not significantly reduce cardiovascular events in patients with atrial fibrillation, according to\u00a0the results of the\u00a0Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE I), published in the New England Journal of Medicine. Participants had been previously randomized in the\u00a0ACTIVE A trial or the\u00a0ACTIVE W trial. More than [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,14],"tags":[647,341,729],"class_list":["post-6803","post","type-post","status-publish","format-standard","hentry","category-electrophysiology","category-heart-failure","tag-arbs","tag-atrial-fibrillation","tag-irbesartan"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/6803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=6803"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/6803\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=6803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=6803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=6803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}